FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

John Kavanagh

Research Profile

Disorders

Procedures

Chemicals & Drugs

Physiology

Drug Resistance, Neoplasm

Concepts & Ideas

Co-author Network

Publications

TOP 3
Siqing Fu; David M Gershenson; Zhen Hong; Jie Huang; John J Kavanagh; Yanfang Li; Tao Liu; Anil K Sood; Robert C Bast; Aiping Chen; Wei Hu
Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3.
Siqing Fu; David M Gershenson; Bryan T Hennessy; Adrienne Howard; Ed Jackson; Zhenlin Ju; John J Kavanagh; Vikas Kundra; Razelle Kurzrock; Charles F Levenback; Jane Li; Yang Li; Maurie Markman; Edward Atkinson; Robert C Bast; Robert L Coleman; Kevin R Coombes; Kristine Dice; Mary Dyer; Chaan S Ng; Anil K Sood; Katherine Stemke-Hale; Judith K Wolf; Gordon B Mills
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.
David M Gershenson; Revathy B Iyer; John J Kavanagh; Anais L Malpica; Kathleen M Schmeler; Charlotte C Sun; Diane C Bodurka; Michael Deavers
Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of John Kavanagh (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Siqing Fu; David M Gershenson; Zhen Hong; Jie Huang; John J Kavanagh; Yanfang Li; Tao Liu; Anil K Sood; Robert C Bast; Aiping Chen; Wei Hu
Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3.
Cancer biology & therapy 2012;13(11):1034-41.
2012: Siqing Fu; David M Gershenson; Bryan T Hennessy; Adrienne Howard; Ed Jackson; Zhenlin Ju; John J Kavanagh; Vikas Kundra; Razelle Kurzrock; Charles F Levenback; Jane Li; Yang Li; Maurie Markman; Edward Atkinson; Robert C Bast; Robert L Coleman; Kevin R Coombes; Kristine Dice; Mary Dyer; Chaan S Ng; Anil K Sood; Katherine Stemke-Hale; Judith K Wolf; Gordon B Mills
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.
Gynecologic oncology 2012;126(1):47-53.
2012: David M Gershenson; Revathy B Iyer; John J Kavanagh; Anais L Malpica; Kathleen M Schmeler; Charlotte C Sun; Diane C Bodurka; Michael Deavers
Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum.
Gynecologic oncology 2012;125(3):661-6.
2011: X Cheng; G Yang; Kathleen M Schmeler; Robert L Coleman; X Tu; Jinsong Liu; John J Kavanagh
Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy.
Gynecologic oncology 2011;121(2):323-7.
2011: Siqing Fu; Wei Hu; Revathy Iyer; John J Kavanagh; Robert L Coleman; Charles F Levenback; Anil K Sood; Judith K Wolf; David M Gershenson; Maurie Markman; Bryan T Hennessy; Razelle Kurzrock; Robert C Bast
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.
Cancer 2011;117(8):1661-9.
2010: Tarinee Manchana; Chupong Ittiwut; Apiwat Mutirangura; John J Kavanagh
Targeted therapies for rare gynaecological cancers.
The lancet oncology 2010;11(7):685-93.
2009: Hong Zheng; Wei Hu; Michael T Deavers; De-Yu Shen; Siqing Fu; Yan-Fang Li; John J Kavanagh
Nuclear cyclin B1 is overexpressed in low-malignant-potential ovarian tumors but not in epithelial ovarian cancer.
American journal of obstetrics and gynecology 2009;201(4):367.e1-6.
2009: David M Gershenson; Charlotte C Sun; Diane C Bodurka; Robert L Coleman; Karen H Lu; Anil K Sood; Michael Deavers; Anais L Malpica; John J Kavanagh
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
Gynecologic oncology 2009;114(1):48-52.
2009: Atthapon Jaishuen; Camilo Jimenez; Nakarin Sirisabya; Yanfang Li; Hong Zheng; Wei Hu; Diana L Urbauer; John J Kavanagh
Poor survival outcome with moderate and severe hypercalcemia in gynecologic malignancy patients.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009;19(2):178-85.
2009: Yanfang Li; Wei Hu; De-Yu Shen; John J Kavanagh; Siqing Fu
Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis.
American journal of obstetrics and gynecology 2009;200(2):177.e1-9.
2008: Xia Tao; Hye S Chon; Siqing Fu; John J Kavanagh; Wei Hu
Update on aurora kinase inhibitors in gynecologic malignancies.
Recent patents on anti-cancer drug discovery 2008;3(3):162-77.
2008: Hong Zheng; Wei Hu; Dongfang Yu; De-Yu Shen; Siqing Fu; John J Kavanagh; I-Chien Wei; David J Yang
Diammine dicarboxylic acid platinum enhances cytotoxicity in platinum-resistant ovarian cancer cells through induction of apoptosis and S-phase cell arrest.
Pharmaceutical research 2008;25(10):2272-82.
2008: Xia Tao; Wei Hu; Pedro T Ramirez; John J Kavanagh
Chemotherapy for recurrent and metastatic cervical cancer.
Gynecologic oncology 2008;110(3 Suppl 2):S67-71.
2008: Pedro T Ramirez; Kathleen M Schmeler; Michael R Milam; Brian M Slomovitz; Judith A Smith; John J Kavanagh; Michael Deavers; Charles Levenback; Robert L Coleman; David M Gershenson
Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum.
Gynecologic oncology 2008;110(1):56-9.
2008: Y F Li; Wei Hu; SQ Fu; J D Li; J H Liu; John J Kavanagh
Aromatase inhibitors in ovarian cancer: is there a role?
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2008;18(4):600-14.
2008: N Sirisabya; Y Li; A Jaishuen; H G Zheng; David M Gershenson; John J Kavanagh
Tamoxifen is safe and effective in gynecological cancer patients with renal dysfunction.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2008;18(4):648-51.
2008: John J Kavanagh; M W Sill; Pedro T Ramirez; D Warshal; M L Pearl; M A Morgan
Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2008;18(3):460-4.
2008: A Jaishuen; Javier P Berrios-Rivera; N Sirisabya; H G Zheng; Y Li; John J Kavanagh
Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2008;18(2):379-83.
2008: M C Boruban; A Jaishuen; N Sirisabya; Ying Li; H G Zheng; Michael T Deavers; John J Kavanagh
Ovarian endometriosis associated with carcinoma and sarcoma: case report.
European journal of gynaecological oncology 2008;29(4):393-6.
2008: Siriwan Tangjitgamol; Sumonmal Manusirivithaya; Jitti Hanprasertpong; John J Kavanagh
Hormone replacement therapy after treatment of endometrial cancer.
Gynecologic and obstetric investigation 2008;65(1):35-8.
2007: John J Kavanagh
Intraperitoneal chemotherapy in the treatment of ovarian cancer.
Journal of surgical oncology 2007;96(7):541-2.
2007: Yanfang Li; Kevin W Finkel; Wei Hu; Siqing Fu; Jihong Liu; Robert Coleman; John J Kavanagh
Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction.
Gynecologic oncology 2007;106(2):375-80.
2007: Y F Li; Siqing Fu; Wei Hu; J H Liu; Kevin W Finkel; David M Gershenson; John J Kavanagh
Systemic anticancer therapy in gynecological cancer patients with renal dysfunction.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2007;17(4):739-63.
2007: H Zheng; John J Kavanagh; Wei Hu; Q Liao; Siqing Fu
Hormonal therapy in ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2007;17(2):325-38.
2006: Siqing Fu; John J Kavanagh; Wei Hu; Robert C Bast
Clinical application of oxaliplatin in epithelial ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16(5):1717-32.
2006: X Wang; Siqing Fu; Ralph S Freedman; Jinsong Liu; John J Kavanagh
Immunobiology of gestational trophoblastic diseases.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16(4):1500-15.
2006: Hye Sook Chon; Wei Hu; John J Kavanagh
Targeted therapies in gynecologic cancers.
Current cancer drug targets 2006;6(4):333-63.
2006: Daniel G Rosen; Gong Yang; Michael T Deavers; Anais Malpica; John J Kavanagh; Gordon B Mills; Jinsong Liu
Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma.
Cancer 2006;106(9):1925-32.
2006: Robert L Coleman; Russell R Broaddus; Diane C Bodurka; Judith K Wolf; Thomas W Burke; John J Kavanagh; Charles Levenback; David M Gershenson
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.
Gynecologic oncology 2006;101(1):126-31.
2006: Siqing Fu; Wei Hu; John J Kavanagh; Robert C Bast
Targeting Aurora kinases in ovarian cancer.
Expert opinion on therapeutic targets 2006;10(1):77-85.
2006: E-J Lee; Michael T Deavers; J I Hughes; Je-Ho Lee; John J Kavanagh
Metastasis to sigmoid colon mucosa and submucosa from serous borderline ovarian tumor: response to hormone therapy.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16 Suppl 1():295-9.
2005: X Wang; Siriwan Tangjitgamol; Jinsong Liu; John J Kavanagh
Response of recurrent uterine high-grade malignant mixed müllerian tumor to letrozole.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2005;15(6):1243-8.
2005: Siriwan Tangjitgamol; Julie Erlichman; H Northrup; Anais Malpica; X Wang; E Lee; John J Kavanagh
Benign multicystic peritoneal mesothelioma: cases reports in the family with diverticulosis and literature review.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2005;15(6):1101-7.
2005: Siriwan Tangjitgamol; Pedro T Ramirez; C C Sun; Hui-Ti See; Anuja Jhingran; John J Kavanagh; Michael T Deavers
Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic study.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2005;15(4):646-56.
2005: John J Kavanagh; David M Gershenson; H Choi; L Lewis; K Patel; G L Brown; A Garcia; David Spriggs
Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2005;15(4):593-600.
2005: Xipeng Wang; Ena Wang; John J Kavanagh; Ralph S Freedman
Ovarian cancer, the coagulation pathway, and inflammation.
Journal of translational medicine 2005;3():25.
2005: Hui-Ti See; Ralph S Freedman; A P Kudelka; Thomas W Burke; David M Gershenson; Siriwan Tangjitgamol; John J Kavanagh
Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2005;15(2):209-16.
2005: Eun-Ju Lee; Cristian Mircean; Ilya Shmulevich; Huamin Wang; Jinsong Liu; Antti Niemistö; John J Kavanagh; Je-Ho Lee; Wei Zhang
Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion.
Molecular cancer 2005;4(1):7.
2005: Wei Hu; John J Kavanagh; Michael Deaver; Dennis A Johnston; Ralph S Freedman; Claire F Verschraegen; Subrata Sen
Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer.
Oncology research 2005;15(1):49-57.
2004: Wei Hu; Weiguo Wu; Ryuji Kobayashi; John J Kavanagh
Proteomics in cancer screening and management in gynecologic cancer.
Current oncology reports 2004;6(6):456-62.
2004: Siriwan Tangjitgamol; Hui-Ti See; Sumonmal Manusirivithaya; Charles Levenback; David M Gershenson; John J Kavanagh
Third-line chemotherapy in platinum- and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2004;14(5):804-14.
2004: Siriwan Tangjitgamol; Charles Levenback; U Beller; John J Kavanagh
Role of surgical resection for lung, liver, and central nervous system metastases in patients with gynecological cancer: a literature review.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2004;14(3):399-422.
2004: Hui-Ti See; John J Kavanagh
Novel agents in epithelial ovarian cancer.
Cancer investigation 2004;22 Suppl 2():29-44.
2004: Claire F Verschraegen; Andrzej P Kudelka; Wei Hu; Monique Vincent; John J Kavanagh; Evelyne M Loyer; Luc Bastien; A Duggal; Robert L De Jager
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
Cancer chemotherapy and pharmacology 2004;53(1):1-7.
2003: Wei Hu; John J Kavanagh
Anticancer therapy targeting the apoptotic pathway.
The lancet oncology 2003;4(12):721-9.
2003: Hui-Ti See; John J Kavanagh; Wei Hu; Robert C Bast
Targeted therapy for epithelial ovarian cancer: current status and future prospects.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2003;13(6):701-34.
2003: Ralph S Freedman; Saroj Vadhan-Raj; Cherie Butts; Cherylyn A Savary; Bohuslav Melichar; Claire F Verschraegen; John J Kavanagh; Marshall E Hicks; Lawrence B Levy; Jody Folloder; Michael E Garcia
Pilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(14):5228-37.
2003: Wei Hu; WeiGuo Wu; Claire F Verschraegen; Ling Chen; Li Mao; Sai-Ching Jim Yeung; Andrzej P Kudelka; Ralph S Freedman; John J Kavanagh
Proteomic identification of heat shock protein 70 as a candidate target for enhancing apoptosis induced by farnesyl transferase inhibitor.
Proteomics 2003;3(10):1904-11.
2003: Bohuslav Melichar; Renato Lenzi; Michael Rosenblum; Andrzej P Kudelka; John J Kavanagh; Karolina Melicharova; Stacie Templin; Michael E Garcia; James L Abbruzzese; Ralph S Freedman
Intraperitoneal fluid neopterin, nitrate, and tryptophan after regional administration of interleukin-12.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2003;26(3):270-6.
2003: Alberto Montero; C Marcela Díaz-Montero; Anais Malpica; Pedro T Ramirez; John J Kavanagh
Langerhans cell histiocytosis of the female genital tract: a literature review.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2003;13(3):381-8.
2003: Claire F Verschraegen; Wei Hu; Yu Du; John Mendoza; Janet Early; Michael Deavers; Ralph S Freedman; Robert C Bast; Andrzej P Kudelka; John J Kavanagh; Beppino C Giovanella
Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(2):845-52.
2003: Diane C Bodurka; Charles Levenback; Judith K Wolf; Jacalyn B Gano; J Taylor Wharton; John J Kavanagh; David M Gershenson
Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(2):291-7.
2002: Renato Lenzi; Michael Rosenblum; Claire F Verschraegen; Andrzej P Kudelka; John J Kavanagh; Marshall E Hicks; Eric A Lang; Michael A Nash; Lawrence B Levy; Michael E Garcia; Chris D Platsoucas; James L Abbruzzese; Ralph S Freedman
Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(12):3686-95.
2002: Charlotte C Sun; Diane C Bodurka; Michele L Donato; Edward B Rubenstein; Candice L Borden; Karen Basen-Engquist; Mark F Munsell; John J Kavanagh; David M Gershenson
Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time?
Gynecologic oncology 2002;87(1):118-28.
2002: Weiguo Wu; Wei Hu; John J Kavanagh
Proteomics in cancer research.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2002;12(5):409-23.
2002: Saroj Vadhan-Raj; John J Kavanagh; Ralph S Freedman; Jody Folloder; Laura M Currie; Carlos E Bueso-Ramos; Claire F Verschraegen; Aida Narvios; Jerome Connor; W Keith Hoots; Lyle D Broemeling; Benjamin Lichtiger
Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.
Lancet 2002;359(9324):2145-52.
2002: John J Kavanagh
Docetaxel in the treatment of ovarian cancer.
Oncology (Williston Park, N.Y.) 2002;16(6 Suppl 6):73-81.
2002: Wei Hu; Weiguo Wu; Sai-Ching Jim Yeung; Ralph S Freedman; John J Kavanagh; Claire F Verschraegen
Increased expression of heat shock protein 70 in adherent ovarian cancer and mesothelioma following treatment with manumycin, a farnesyl transferase inhibitor.
Anticancer research 2002;22(2A):665-72.
2002: Wei Hu; Claire F Verschraegen; WG Wu; M Nash; Ralph S Freedman; Andrzej P Kudelka; John J Kavanagh
Activity of ALRT 1550, a new retinoid, with interferon-gamma on ovarian cancer cell lines.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2002;12(2):202-7.
2001: Claire F Verschraegen; John J Kavanagh; Evelyne M Loyer; DC Bodurka-Bevers; Andrzej P Kudelka; W Hu; M Vincent; T Nelson; Charles Levenback
Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix.
Cancer 2001;92(9):2327-33.
2001: Claire F Verschraegen; M Benjapibal; W Supakarapongkul; Lawrence B Levy; Merrick Ross; E Neely Atkinson; DC Bodurka-Bevers; John J Kavanagh; Andrzej P Kudelka; Sewa S Legha
Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years later.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2001;11(5):359-64.
2001: P Azevedo; Claire F Verschraegen; John J Kavanagh; Andrzej P Kudelka; Ralph S Freedman; K Lu; M T Deavers
Malignant mixed mesodermal tumor of the ovary treated with a cisplatin-irinotecan combination: case report.
European journal of gynaecological oncology 2001;22(5):319-21.
2000: C Moon; Claire F Verschraegen; M Bevers; R Freedman; Andrzej P Kudelka; John J Kavanagh
Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity.
Anti-cancer drugs 2000;11(7):565-8.
2000: Claire F Verschraegen; T Sittisomwong; Andrzej P Kudelka; E d Guedes; Melissa Steger; T Nelson-Taylor; Monique Vincent; R Rogers; E Neely Atkinson; John J Kavanagh
Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(14):2733-9.
2000: Ralph S Freedman; Andrzej P Kudelka; John J Kavanagh; Claire F Verschraegen; Creighton L Edwards; M Nash; L Levy; E Neely Atkinson; Hua-Zhong Zhang; Bohuslav Melichar; Rebecca Patenia; Stacie Templin; W Scott; Chris D Platsoucas
Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(6):2268-78.
2000: Saroj Vadhan-Raj; Claire F Verschraegen; Carlos E Bueso-Ramos; Hal E Broxmeyer; A P Kudelkà; Ralph S Freedman; Creighton L Edwards; David M Gershenson; Denny Jones; Mark Ashby; John J Kavanagh
Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer.
Annals of internal medicine 2000;132(5):364-8.
2000: Wei Hu; Weiguo Wu; Michael A Nash; Ralph S Freedman; John J Kavanagh; Claire F Verschraegen
Anomalies of the TGF-beta postreceptor signaling pathway in ovarian cancer cell lines.
Anticancer research 2000;20(2A):729-33.
2000: Wei Hu; Pierre D McCrea; Michael Deavers; John J Kavanagh; Andrzej P Kudelka; Claire F Verschraegen
Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors.
Clinical & experimental metastasis 2000;18(1):83-8.
2000: Claire F Verschraegen; Charles Levenback; Monique Vincent; J Wolf; Michael W Bevers; Evelyne M Loyer; Andrzej P Kudelka; John J Kavanagh
Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan.
Annals of the New York Academy of Sciences 2000;922():349-51.
2000: Claire F Verschraegen; Monique Vincent; James L Abbruzzese; D Siegler; John J Kavanagh; Evelyne M Loyer; Andrzej P Kudelka; E Rubin
Phase I study of 9-nitro-20(S)-camptothecin in combination with cisplatin for patients with advanced malignancies.
Annals of the New York Academy of Sciences 2000;922():345-8.
2000: T Sittisomwong; A Suneja; Andrzej P Kudelka; Claire F Verschraegen; John J Kavanagh
Estrogen replacement therapy and ovarian cancer.
European journal of gynaecological oncology 2000;21(4):348-54.
1999: AE Loercher; Michael A Nash; John J Kavanagh; Chris D Platsoucas; Ralph S Freedman
Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(11):6251-60.
1999: Michael G Rosenblum; Claire F Verschraegen; James L Murray; Andrzej P Kudelka; Jacalyn B Gano; Lawrence Cheung; John J Kavanagh
Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(5):953-61.
1999: Claire F Verschraegen; E Gupta; Evelyne M Loyer; John J Kavanagh; Andrzej P Kudelka; Ralph S Freedman; Creighton L Edwards; Nick Harris; Melissa Steger; V Steltz; Beppino C Giovanella; John S Stehlin
A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer.
Anti-cancer drugs 1999;10(4):375-83.
1998: Andrzej P Kudelka; A Vasuratna; Creighton L Edwards; K Augustine; M Benjapibal; Claire F Verschraegen; John J Kavanagh
Gemcitabine after bone marrow transplantation for refractory juvenile granulosa cell tumor.
Anti-cancer drugs 1998;9(7):621-3.
1998: John J Kavanagh; Claire F Verschraegen; Andrzej P Kudelka
Irinotecan in cervical cancer.
Oncology (Williston Park, N.Y.) 1998;12(8 Suppl 6):94-8.
1998: M Benjapibal; Andrzej P Kudelka; A Vasuratna; Creighton L Edwards; Claire F Verschraegen; V Valero; Saroj Vadhan-Raj; John J Kavanagh
Docetaxel and cyclophosphamide induced remission in platinum and paclitaxel refractory ovarian cancer.
Anti-cancer drugs 1998;9(6):577-9.
1998: Claire F Verschraegen; A Vasuratna; C Edwards; R Freedman; Andrzej P Kudelka; Carmen Tornos; John J Kavanagh
Clinicopathologic analysis of mullerian adenosarcoma: the M.D. Anderson Cancer Center experience.
Oncology reports 1998;5(4):939-44.
1998: Andrzej P Kudelka; Annette Hasenburg; Claire F Verschraegen; Creighton L Edwards; Christina A Meyers; D Varma; Ralph S Freedman; Arthur Forman; Charles A Conrad; W Grove; Axel Grothey; John J Kavanagh
Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma.
Anti-cancer drugs 1998;9(5):405-9.
1998: Michael A Nash; Renato Lenzi; Creighton L Edwards; John J Kavanagh; Andrzej P Kudelka; Claire F Verschraegen; Chris D Platsoucas; Ralph S Freedman
Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour-infiltrating lymphocyte (TIL)-derived T cell lines and established tumour cell lines.
Clinical and experimental immunology 1998;112(2):172-80.
1998: A Vasuratna; Andrzej P Kudelka; Creighton L Edwards; V Wootipoom; Claire F Verschraegen; C Charnsangavej; John J Kavanagh
Prolonged remission of endometrial cancer with paclitaxel and carboplatin.
Anti-cancer drugs 1998;9(3):283-5.
1998: Bohuslav Melichar; Cherylyn A Savary; Andrzej P Kudelka; Claire F Verschraegen; John J Kavanagh; Creighton L Edwards; Chris D Platsoucas; Ralph S Freedman
Lineage-negative human leukocyte antigen-DR+ cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(3):799-809.
1998: Claire F Verschraegen; E A Natelson; Beppino C Giovanella; John J Kavanagh; Andrzej P Kudelka; Ralph S Freedman; Creighton L Edwards; K Ende; John S Stehlin
A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor.
Anti-cancer drugs 1998;9(1):36-44.
1997: G Ferrandina; Bohuslav Melichar; AE Loercher; Claire F Verschraegen; Andrzej P Kudelka; Creighton L Edwards; G Scambia; John J Kavanagh; James L Abbruzzese; Ralph S Freedman
Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro.
Cancer research 1997;57(19):4309-15.
1997: Andrzej P Kudelka; T Levy; Claire F Verschraegen; Creighton L Edwards; S Piamsomboon; Wichai Termrungruanglert; Ralph S Freedman; Alan L Kaplan; Dirk G Kieback; Christina A Meyers; Kurt A Jaeckle; Evelyne M Loyer; Melissa Steger; RP Mante; Giora Mavligit; A Killian; R A Tang; Jordan U Gutterman; John J Kavanagh
A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(9):1501-5.
1997: Andrzej P Kudelka; Rodger Winn; Creighton L Edwards; G Downey; H Greenberg; Shaker R Dakhil; Ralph S Freedman; Salvatore J. LoCoco; J Umbreit; J E Delmore; Arbuck Susan; Evelyne M Loyer; P Gacrama; R Fueger; John J Kavanagh
An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix.
Anti-cancer drugs 1997;8(7):657-61.
1997: Andrzej P Kudelka; Zahid H Siddik; D Tresukosol; Creighton L Edwards; Ralph S Freedman; Timothy L Madden; R Rastogi; M Hord; E Edmund Kim; Carmen Tornos; RP Mante; John J Kavanagh
A phase II and pharmacokinetic study of enloplatin in patients with platinum refractory advanced ovarian carcinoma.
Anti-cancer drugs 1997;8(7):649-56.
1997: Koen van Besien; Claire F Verschraegen; R Mehra; Sergio Giralt; Andrzej P Kudelka; Creighton L Edwards; S Piamsonboom; Wichai Termrungruanglert; Richard Champlin; John J Kavanagh
Complete remission of refractory gestational trophoblastic disease with brain metastases treated with multicycle ifosfamide, carboplatin, and etoposide (ICE) and stem cell rescue.
Gynecologic oncology 1997;65(2):366-9.
1997: Wichai Termrungruanglert; Andrzej P Kudelka; Creighton L Edwards; L Delclos; Claire F Verschraegen; John J Kavanagh
Gynecologic cancer in the elderly.
Clinics in geriatric medicine 1997;13(2):363-79.
1997: A A Ashour; Claire F Verschraegen; Andrzej P Kudelka; John J Kavanagh
Paraneoplastic syndromes of gynecologic neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(3):1272-82.
1997: Claire F Verschraegen; T Levy; Andrzej P Kudelka; E Llerena; K Ende; Ralph S Freedman; Creighton L Edwards; M Hord; Melissa Steger; Alan L Kaplan; Dirk G Kieback; Ami Fishman; John J Kavanagh
Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(2):625-31.
1997: S Piamsomboon; Andrzej P Kudelka; Wichai Termrungruanglert; Koen van Besien; Creighton L Edwards; S Lifshitz; D F Schomer; Richard Champlin; RP Mante; John J Kavanagh; Claire F Verschraegen
Remission of refractory gestational trophoblastic disease in the brain with ifosfamide, carboplatin, and etoposide (ICE): first report and review of literature.
European journal of gynaecological oncology 1997;18(6):453-6.
1997: Ozcan Balat; Andrzej P Kudelka; Creighton L Edwards; Claire F Verschraegen; John J Kavanagh
Prolonged remission of platinum-refractory ovarian cancer with docetaxel: brief report and review of literature.
European journal of gynaecological oncology 1997;18(5):341-2.
1997: Wichai Termrungruanglert; Andrzej P Kudelka; S Piamsomboon; Creighton L Edwards; Carmen Tornos; John J Kavanagh
Prolonged oral etoposide for advanced uterine leiomyosarcoma with pulmonary metastases: case report.
European journal of gynaecological oncology 1997;18(2):97-100.
1997: E Llerena; Andrzej P Kudelka; Carmen Tornos; G F Cedillo; A Lopez; Creighton L Edwards; J P Litam; John J Kavanagh
Remission of a chemotherapy resistant tumor of low malignant potential with tamoxifen.
European journal of gynaecological oncology 1997;18(1):23-5.
1996: Ralph S Freedman; J A Gibbons; M Giedlin; Andrzej P Kudelka; John J Kavanagh; Creighton L Edwards; C H Carrasco; Michael A Nash; Chris D Platsoucas
Immunopharmacology and cytokine production of a low-dose schedule of intraperitoneally administered human recombinant interleukin-2 in patients with advanced epithelial ovarian carcinoma.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(6):443-51.
1996: Andrzej P Kudelka; Wichai Termrungruanglert; S Vadhan-Raj; Creighton L Edwards; D G Varma; Carmen Tornos; Claire F Verschraegen; John J Kavanagh
Remission of advanced uterine leiomyosarcoma with pulmonary metastases with carboplatin and paclitaxel.
Anti-cancer drugs 1996;7(8):885-9.
1996: V Wright-Browne; Andrzej P Kudelka; Anais Malpica; Creighton L Edwards; D G Varma; John J Kavanagh
Persistent partial molar pregnancy. A report of uterus-preserving treatment and follow-up with magnetic resonance imaging.
American journal of clinical oncology 1996;19(5):534-9.
1996: S Piamsomboon; Wichai Termrungruanglert; Andrzej P Kudelka; Creighton L Edwards; Ralph S Freedman; C F Mountain; L Delclos; M S Aapro; L DeCaro; J Bianca; Claire F Verschraegen; John J Kavanagh
Prolonged stabilization of progressive squamous cell cancer of the cervix with interferon-alpha and 13-cis-retinoic acid: report of two cases and review of the literature.
Anti-cancer drugs 1996;7(7):800-4.
1996: Andrzej P Kudelka; Rodger Winn; Creighton L Edwards; G Downey; H Greenberg; Shaker R Dakhil; Ralph S Freedman; Evelyne M Loyer; J Rusinkiewicz; P Gacrama; R Fueger; John J Kavanagh
Activity of paclitaxel in advanced or recurrent squamous cell cancer of the cervix.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(8):1285-8.
1996: Claire F Verschraegen; Andrzej P Kudelka; Wichai Termrungruanglert; C G de Leon; Creighton L Edwards; Ralph S Freedman; John J Kavanagh; S Vadhan-Raj
Effects of interleukin-1 alpha on ovarian carcinoma in patients with recurrent disease.
European journal of cancer (Oxford, England : 1990) 1996;32A(9):1609-11.
1996: Wichai Termrungruanglert; Andrzej P Kudelka; S Piamsomboon; Claire F Verschraegen; Creighton L Edwards; S Lifshitz; R P Mante; John J Kavanagh
Remission of refractory gestational trophoblastic disease with high-dose paclitaxel.
Anti-cancer drugs 1996;7(5):503-6.
1996: Andrzej P Kudelka; Claire F Verschraegen; Tally Levy; Creighton L Edwards; Ami Fishman; Ralph S Freedman; A Kaplan; Dirk G Kieback; R Mante; K Ende; Melissa Steger; John J Kavanagh
Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix.
Anti-cancer drugs 1996;7(4):398-401.
1996: Ami Fishman; Andrzej P Kudelka; Damras Tresukosol; Creighton L Edwards; Ralph S Freedman; A L Kaplan; R E Girtanner; John J Kavanagh
Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor.
The Journal of reproductive medicine 1996;41(6):393-6.
1996: John J Kavanagh; Andrzej P Kudelka; C G de Leon; Damras Tresukosol; M Hord; M B Finnegan; E Edmund Kim; D Varma; A Forman; P Cohen; Creighton L Edwards; Ralph S Freedman; Claire F Verschraegen
Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(5):837-42.
1996: Damras Tresukosol; Andrzej P Kudelka; Creighton L Edwards; E G Silva; M Kanojia; John J Kavanagh
Leuprolide acetate in advanced ovarian serous tumor of low malignant potential. A case report.
The Journal of reproductive medicine 1996;41(5):363-6.
1996: Andrzej P Kudelka; Damras Tresukosol; Creighton L Edwards; Ralph S Freedman; Charles Levenback; P Chantarawiroj; C Gonzalez de Leon; E Edmund Kim; Timothy Madden; B Wallin; M Hord; Claire F Verschraegen; Martin N Raber; John J Kavanagh
Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(5):1552-7.
1996: Andrzej P Kudelka; Damras Tresukosol; C Gonzalez de Leon; Wichai Termrungruanglert; Creighton L Edwards; Ralph S Freedman; Carmen Tornos; John J Kavanagh
Paclitaxel in patients with platinum-resistant ovarian cancer: a selected review of literature and clinical experience.
Journal of the Medical Association of Thailand = Chotmaihet thangphaet 1996;79(4):240-5.
1996: Wichai Termrungruanglert; Andrzej P Kudelka; S Piamsomboon; Creighton L Edwards; Claire F Verschraegen; Evelyne M Loyer; John J Kavanagh
Remission of recurrent cervical cancer with paclitaxel and carboplatin: a case report and review of literature.
European journal of gynaecological oncology 1996;17(6):493-6.
1996: Y C Lin; Andrzej P Kudelka; D Lawrence; Claire F Verschraegen; John J Kavanagh; Creighton L Edwards; R Mante; Ralph S Freedman
Transcatheter arterial embolization for the control of life-threatening pelvic hemorrhage in a patient with locally advanced cervix carcinoma.
European journal of gynaecological oncology 1996;17(6):480-3.
1996: O Balat; Andrzej P Kudelka; Creighton L Edwards; Claire F Verschraegen; John J Kavanagh
Remission of recurrent mixed germ cell tumor of the ovary after treatment with vincristine, carboplatin, fluorouracil, and ifosfamide: a case report and review of the literature.
European journal of gynaecological oncology 1996;17(5):342-4.
1996: O Balat; Claire F Verschraegen; Creighton L Edwards; E Silva; Andrzej P Kudelka; John J Kavanagh
Unusual presentation of a metastatic choriocarcinoma following a full term pregnancy: a case report.
European journal of gynaecological oncology 1996;17(4):271-3.
1996: O Balat; Andrzej P Kudelka; J C Tunca; Creighton L Edwards; Claire F Verschraegen; John J Kavanagh
Prolonged stabilization of progressive platinum-refractory ovarian cancer with paclitaxel: brief report.
European journal of gynaecological oncology 1996;17(4):264-6.
1996: O Balat; Andrzej P Kudelka; Jae Y Ro; Creighton L Edwards; D Balbay; C Dinney; John J Kavanagh
Two synchronous primary tumors of the ovary and kidney: a case report.
European journal of gynaecological oncology 1996;17(4):257-9.
1996: O Balat; Andrzej P Kudelka; Creighton L Edwards; Claire F Verschraegen; R Mante; John J Kavanagh
A case report of paclitaxel administered to a patient with platinum-refractory ovarian cancer on long-term hemodialysis.
European journal of gynaecological oncology 1996;17(3):232-3.
1996: Damras Tresukosol; Andrzej P Kudelka; C Gonzales de Leon; Creighton L Edwards; Ralph S Freedman; R Mante; M Hord; John J Kavanagh
Paclitaxel retreatment in patients with platinum and paclitaxel resistant ovarian cancer.
European journal of gynaecological oncology 1996;17(3):188-91.
1996: O Balat; Andrzej P Kudelka; Creighton L Edwards; E Silva; John J Kavanagh
Malignant transformation in endometriosis of the urinary bladder: case report of clear cell adenocarcinoma.
European journal of gynaecological oncology 1996;17(1):13-6.
1995: J A Romero; E Edmund Kim; Damras Tresukosol; Andrzej P Kudelka; Creighton L Edwards; John J Kavanagh
Recurrent ovarian endodermal sinus tumor: demonstration by computed tomography, magnetic resonance imaging, and positron emission tomography.
European journal of nuclear medicine 1995;22(10):1214-7.
1995: Damras Tresukosol; Andrzej P Kudelka; Anais Malpica; D G Varma; Creighton L Edwards; John J Kavanagh
Leuprolide acetate and intravascular leiomyomatosis.
Obstetrics and gynecology 1995;86(4 Pt 2):688-92.
1995: David M Gershenson; Mitchell Morris; Thomas W Burke; Charles Levenback; John J Kavanagh; G L Fromm; Elvio G Silva; D Warner; J Taylor Wharton
Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer.
Gynecologic oncology 1995;58(3):349-55.
1995: Andrzej P Kudelka; Z M Siddik; O Balat; John J Kavanagh
Carboplatin dosimetry in renal failure.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(8):2147-8.
1995: Y C Lin; Andrzej P Kudelka; Damras Tresukosol; Anais Malpica; C H Carrasco; DD Lawrence; R E Collier; A Munoz; L Delclos; John J Kavanagh
Prolonged stabilization of progressive endometrial stromal sarcoma with prolonged oral etoposide therapy.
Gynecologic oncology 1995;58(2):262-5.
1995: Damras Tresukosol; Andrzej P Kudelka; Creighton L Edwards; G L Fromm; R Mante; John J Kavanagh
Primary fallopian tube adenocarcinoma: clinical complete response after salvage treatment with high-dose paclitaxel.
Gynecologic oncology 1995;58(2):258-61.
1995: P Chantarawiroj; Damras Tresukosol; Andrzej P Kudelka; Creighton L Edwards; E G Silva; J T Wharton; John J Kavanagh
Prolonged oral etoposide for refractory advanced uterine leiomyosarcoma.
Gynecologic oncology 1995;58(2):248-50.
1995: John J Kavanagh; Creighton L Edwards; Ralph S Freedman; M B Finnegan; O Balat; Damras Tresukosol; K Burk; S Loechner; M Hord; J L Franklin
A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer.
Gynecologic oncology 1995;58(1):106-9.
1995: Mitchell Morris; Patricia J Eifel; Thomas W Burke; M M McNamara; Charles Levenback; John J Kavanagh; David M Gershenson
Treatment of locally advanced cervical cancer with concurrent radiation and intra-arterial chemotherapy.
Gynecologic oncology 1995;57(1):72-8.
1995: R Vassilopoulou-Sellin; Andrzej P Kudelka; John J Kavanagh; Creighton L Edwards; S Vadhan-Raj
Effects of interleukin-1 alpha administration on pituitary-adrenal and pituitary-thyroid axes function of patients with ovarian cancer.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;17(2):109-13.
1995: S Wilailak; Andrzej P Kudelka; L R Donner; E Silva; R Mante; John J Kavanagh
Peritoneal papillary serous carcinoma: response to Taxol in platinum resistant disease.
European journal of gynaecological oncology 1995;16(3):187-9.
1994: Elizabeth A Eisenhauer; Scott M Lippman; John J Kavanagh; M Parades-Espinoza; A Arnold; Waun Ki Hong; G Massimini; U Schleuniger; W Bollag; E E Holdener
Combination 13-cis-retinoic acid and interferon alpha-2a in the therapy of solid tumors.
Leukemia 1994;8(10):1622-5.
1994: Ralph S Freedman; Creighton L Edwards; John J Kavanagh; Andrzej P Kudelka; Ruth Katz; C H Carrasco; E Neely Atkinson; W Scott; B Tomasovic; S Templin
Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;16(3):198-210.
1994: D M Moore; Dhan V Kalvakolanu; Scott M Lippman; John J Kavanagh; Waun Ki Hong; Ernest C Borden; M Paredes-Espinoza; I H Krakoff
Retinoic acid and interferon in human cancer: mechanistic and clinical studies.
Seminars in hematology 1994;31(4 Suppl 5):31-7.
1994: J A Romero; E Edmund Kim; Andrzej P Kudelka; Creighton L Edwards; John J Kavanagh
MRI of recurrent cystic mesothelioma: differential diagnosis of cystic pelvic masses.
Gynecologic oncology 1994;54(3):377-80.
1994: Saroj Vadhan-Raj; Andrzej P Kudelka; L Garrison; Jacalyn B Gano; Creighton L Edwards; Ralph S Freedman; John J Kavanagh
Effects of interleukin-1 alpha on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(4):707-14.
1994: M Paredes Espinoza; Scott M Lippman; John J Kavanagh; F Delgadillo Madrueño; P Paredes Casillas; O Bañuelos Acosta; V Alvarez Márquez; M A Buenrostro Ahued; I de Alba Ayala; G Arias Castro
[Treatment of 32 cervico-uterine cancer patients with 13-cis-retinoic acid and interferon alpha].
Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición 1994;46(2):105-11.
1994: Elizabeth A Eisenhauer; Scott M Lippman; John J Kavanagh; M Parades-Espinoza; A Arnold; Waun Ki Hong; G Massimini; U Schleuniger; W Bollag; E E Holdener
Combination 13-cis-retinoic acid and interferon alpha-2a in the therapy of solid tumors.
Leukemia 1994;8 Suppl 3():S38-41.
1993: Thomas W Burke; Adnan R Munkarah; John J Kavanagh; Mitchell Morris; Charles Levenback; Carmen Tornos; David M Gershenson
Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin.
Gynecologic oncology 1993;51(3):397-400.
1993: John J Kavanagh; Andrzej P Kudelka
Systemic therapy for gynecologic cancer.
Current opinion in oncology 1993;5(5):891-9.
1993: L D Roman; MF Mitchell; Carmen Tornos; A Glover; John J Kavanagh
Dedifferentiated extrauterine adenosarcoma responsive to chemotherapy.
Gynecologic oncology 1993;49(3):389-94.
1993: Scott M Lippman; John J Kavanagh; M Paredes-Espinoza; F Delgadillo-Madrueño; P Paredes-Casillas; Waun Ki Hong; G Massimini; E E Holdener; I H Krakoff
13-cis-retinoic acid plus interferon-alpha 2a in locally advanced squamous cell carcinoma of the cervix.
Journal of the National Cancer Institute 1993;85(6):499-500.
1993: I R Kirk; C H Carrasco; DD Lawrence; V P Chuang; W R Richli; Chusilp Charnsangavej; John J Kavanagh; Andrzej P Kudelka; R S Freedman; A B Markowitz
Intraperitoneal catheters: percutaneous placement with fluoroscopic guidance.
Journal of vascular and interventional radiology : JVIR 1993;4(2):299-304.
1993: David M Gershenson; MF Mitchell; N Atkinson; Elvio G Silva; Thomas W Burke; Mitchell Morris; John J Kavanagh; D Warner; J Taylor Wharton
Age contrasts in patients with advanced epithelial ovarian cancer. The M.D. Anderson Cancer Center experience.
Cancer 1993;71(2 Suppl):638-43.
1993: Scott M Lippman; Bonnie S Glisson; John J Kavanagh; R Lotan; Waun Ki Hong; M Paredes-Espinoza; W N Hittelman; E E Holdener; I H Krakoff
Retinoic acid and interferon combination studies in human cancer.
European journal of cancer (Oxford, England : 1990) 1993;29A Suppl 5():S9-13.
1993: Harriet O Smith; C Allen Stringer; John J Kavanagh; David M Gershenson; Creighton L Edwards; J Taylor Wharton
Treatment of advanced or recurrent squamous cell carcinoma of the uterine cervix with mitomycin-C, bleomycin, and cisplatin chemotherapy.
Gynecologic oncology 1993;48(1):11-5.
1992: David M Gershenson; MF Mitchell; N Atkinson; Elvio G Silva; John J Kavanagh; Mitchell Morris; Thomas W Burke; D Warner; J Taylor Wharton
The effect of prolonged cisplatin-based chemotherapy on progression-free survival in patients with optimal epithelial ovarian cancer: "maintenance" therapy reconsidered.
Gynecologic oncology 1992;47(1):7-13.
1992: Charles Levenback; Thomas W Burke; E Silva; Mitchell Morris; David M Gershenson; John J Kavanagh; J Taylor Wharton
Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC).
Gynecologic oncology 1992;46(3):317-21.
1992: Scott M Lippman; John J Kavanagh; M Paredes-Espinoza; F Delgadillo-Madrueño; P Paredes-Casillas; Waun Ki Hong; E Holdener; I H Krakoff
13-cis-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix.
Journal of the National Cancer Institute 1992;84(4):241-5.
1991: Michael G Rosenblum; John J Kavanagh; T W Burke; J T Wharton; Joan E. Cunningham; L J Shanken; E G Silva; L Thompson; L Cheung; L Lamki
Clinical pharmacology, metabolism, and tissue distribution of 90Y-labeled monoclonal antibody B72.3 after intraperitoneal administration.
Journal of the National Cancer Institute 1991;83(22):1629-36.
1991: T J Patton; John J Kavanagh; L Delclos; Sidney Wallace; T P Haynie; David M Gershenson; J Taylor Wharton; S Bass
Five-year survival in patients given intra-arterial chemotherapy prior to radiotherapy for advanced squamous carcinoma of the cervix and vagina.
Gynecologic oncology 1991;42(1):54-9.
1991: Thomas W Burke; C Allen Stringer; Mitchell Morris; Ralph S Freedman; David M Gershenson; John J Kavanagh; Creighton L Edwards
Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide.
Gynecologic oncology 1991;40(3):264-7.
1991: G Baiocchi; John J Kavanagh; Moshe Talpaz; J Taylor Wharton; Jordan U Gutterman; Razelle Kurzrock
Expression of the macrophage colony-stimulating factor and its receptor in gynecologic malignancies.
Cancer 1991;67(4):990-6.
1990: Mitchell Morris; David M Gershenson; Thomas W Burke; John J Kavanagh; Elvio G Silva; J Taylor Wharton
Treatment of fallopian tube carcinoma with cisplatin, doxorubicin, and cyclophosphamide.
Obstetrics and gynecology 1990;76(6):1020-4.
1990: J H Lee; John J Kavanagh; David M Wildrick; J Taylor Wharton; M Blick
Frequent loss of heterozygosity on chromosomes 6q, 11, and 17 in human ovarian carcinomas.
Cancer research 1990;50(9):2724-8.
1990: David M Gershenson; Mitchell Morris; A Cangir; John J Kavanagh; C Allen Stringer; Creighton L Edwards; Elvio G Silva; J Taylor Wharton
Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(4):715-20.
1989: David M Gershenson; John J Kavanagh; Larry J Copeland; C Allen Stringer; Mitchell Morris; J Taylor Wharton
Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy.
Obstetrics and gynecology 1989;73(5 Pt 1):798-802.
1989: John J Kavanagh; C Nicaise
Carboplatin in refractory epithelial ovarian cancer.
Seminars in oncology 1989;16(2 Suppl 5):45-8.
1989: David M Gershenson; J Taylor Wharton; Larry J Copeland; C Allen Stringer; Creighton L Edwards; John J Kavanagh; Ralph S Freedman
Treatment of advanced epithelial ovarian cancer with cisplatin and cyclophosphamide.
Gynecologic oncology 1989;32(3):336-41.
1989: J H Lee; John J Kavanagh; J Taylor Wharton; David M Wildrick; M Blick
Allele loss at the c-Ha-ras1 locus in human ovarian cancer.
Cancer research 1989;49(5):1220-2.
1989: John J Kavanagh; W Roberts; P Townsend; S Hewitt
Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(1):115-8.
1987: David M Gershenson; Larry J Copeland; John J Kavanagh; C Allen Stringer; P B Saul; J Taylor Wharton
Treatment of metastatic stromal tumors of the ovary with cisplatin, doxorubicin, and cyclophosphamide.
Obstetrics and gynecology 1987;70(5):765-9.
1987: John J Kavanagh; P B Saul; J Taylor Wharton; F N Rutledge
A trial of continuous-infusion vinblastine in refractory endometrial adenocarcinoma.
Gynecologic oncology 1987;26(2):236-9.
1986: Alan N Gordon; John J Kavanagh; David M Gershenson; P B Saul; Larry J Copeland; C Allen Stringer
Cisplatin, vinblastine, and bleomycin combination therapy in resistant gestational trophoblastic disease.
Cancer 1986;58(7):1407-10.
1986: David M Gershenson; John J Kavanagh; Larry J Copeland; G Del Junco; A Cangir; P B Saul; C Allen Stringer; Creighton L Edwards; J Taylor Wharton
Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vinblastine, bleomycin, and cisplatin.
Cancer 1986;57(9):1731-7.
1985: David M Gershenson; Larry J Copeland; John J Kavanagh; A Cangir; G Del Junco; P B Saul; C Allen Stringer; R S Freedman; Creighton L Edwards; J Taylor Wharton
Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vincristine, dactinomycin, and cyclophosphamide.
Cancer 1985;56(12):2756-61.
1985: Larry J Copeland; Nour Sneige; C Allen Stringer; David M Gershenson; P B Saul; John J Kavanagh
Alveolar rhabdomyosarcoma of the female genitalia.
Cancer 1985;56(4):849-55.
1985: John J Kavanagh; Larry J Copeland; David M Gershenson; P B Saul; J Taylor Wharton; F N Rutledge
Continuous-infusion vinblastine in refractory carcinoma of the cervix: a phase II trial.
Gynecologic oncology 1985;21(2):211-4.
1985: Larry J Copeland; Nour Sneige; N G Ordonez; K C Hancock; David M Gershenson; P B Saul; John J Kavanagh
Endodermal sinus tumor of the vagina and cervix.
Cancer 1985;55(11):2558-65.
1985: Alan N Gordon; David M Gershenson; Larry J Copeland; P B Saul; John J Kavanagh; Creighton L Edwards
High-risk metastatic gestational trophoblastic disease.
Obstetrics and gynecology 1985;65(4):550-6.